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Abstract
Background: Ruthenium (Ru) tetraamines are being increasingly used as nitric oxide (NO) carriers. In this context, 
pharmacological studies have become highly relevant to better understand the mechanism of action involved.
Objective: To evaluate the vascular response of the tetraamines trans-[RuII(NH3)4(Py)(NO)]
3+, trans-[RuII(Cl)(NO)
(cyclan)](PF6)2, and trans-[Ru
II(NH3)4(4-acPy)(NO)]
3+.
Methods: Aortic rings were contracted with noradrenaline (10−6 M). After voltage stabilization, a single concentration 
(10−6 M) of the compounds was added to the assay medium. The responses were recorded during 120 min. Vascular 
integrity was assessed functionally using acetylcholine at 10−6 M and sodium nitroprusside at 10−6 M as well as by 
histological examination. 
Results: Histological analysis confirmed the presence or absence of endothelial cells in those tissues. All tetraamine 
complexes altered the contractile response induced by norepinephrine, resulting in increased tone followed by 
relaxation. In rings with endothelium, the inhibition of endothelial NO caused a reduction of the contractile effect 
caused by pyridine NO. No significant responses were observed in rings with endothelium after treatment with cyclan 
NO. In contrast, in rings without endothelium, the inhibition of guanylate cyclase significantly reduced the contractile 
response caused by the pyridine NO and cyclan NO complexes, and both complexes caused a relaxing effect. 
Conclusion: The results indicate that the vascular effect of the evaluated complexes involved a decrease in the vascular 
tone induced by norepinephrine (10−6 M) at the end of the incubation period in aortic rings with and without endothelium, 
indicating the slow release of NO from these complexes and suggesting that the ligands promoted chemical stability to the 
molecule. Moreover, we demonstrated that the association of Ru with NO is more stable when the ligands pyridine and cyclan 
are used in the formulation of the compound. (Arq Bras Cardiol. 2015; 104(3):185-194)
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Introduction
The endothelium plays an important role in the vascular 
system through the production of vasoactive mediators, 
such as nitric oxide (NO)1-3 {Furchgott, 1987 # 14}. 
The impaired vascular function has been the focus 
of research on vasoactive compounds, particularly 
antihypertensive compounds, with the aim to restore 
the amount of NO necessary to achieve hemodynamic 
balance4. Therefore, complexes capable of delivering NO 
efficiently and in a controlled manner have been studied 
not only to understand their chemical nature but also for 
future medical applications. These studies can significantly 
contribute to the treatment of vascular diseases.
NO can serve as a ligand for many transition metals, such 
as iron (Fe), ruthenium (Ru), and chromium (Cr), among 
others. Metal complexes of Ru (II) have become the focus of 
research because of its remarkable ability to bind to various 
compounds. In addition, it is the element that best forms 
nitrosyl complexes5,6.
In this respect, the class of tetraamines of Ru (II) trans-RuII(NO)
(NH3)4(L)]
n+, reported in the literature as [RuIINO+], has 
significant thermal stability in the Ru–NO bond, ligand L being 
the guiding element of this stabilization. The disassociation 
of this bond using a substitution is controlled by the rate 
constant of NO (KNO) via monoelectronic reduction, wherein 
the reductive potential of the ligand should lie between 
0.320 V and 0.132 V4-9.
KNO is important because it determines the duration of the 
vascular effect4.The kinetic constant of NO (kNO ) varies between 
0.02 s−1 (L = 4-pic) and 4 s−1 (L = imC) at 25°C and increases 
in the order: isn ~ pic ~ nic ~ H2O ~ py ~ pz < L-His ~ 
imN < P (OEt)3 < imC
8.
Considering the existing medications and aiming at 
the improvement of clinical applications for treatment of 
vascular diseases, this system is advantageous because of 
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the possibility of the controlled release of NO to specific 
biological targets4,8,10-12.Therefore, the present study 
aimed to investigate the effect of the Ru tetraamines 
trans-[RuII(NH3)4(Py)(NO)]
3+ (PyNO), trans-[RuII(Cl)(NO)
(Cyclan)](PF6)2 (CyNO), and trans-[Ru
II(NH3)4(4-acPy)(NO)]
3+ 
(4-acPyNO) on the vascular response. 
Methods
The protocols used were approved by the Ethics Committee 
on Animal Experimentation of the State University of 
Campinas (Universidade Estadual de Campinas–UNICAMP) 
under protocol number 2099-2. The study was conducted in 
accordance with the standards of the Guide for the Care and 
Use of Laboratory Animals established in 199313 and with the 
Ethical Principles of Animal Experimentation of the Brazilian 
School of Animal Experimentation (Colégio Brasileiro de 
Experimentação Animal–COBEA) from 1991 on the use of 
animals for research and teaching purposes.
Animals
The animals were obtained from the Multidisciplinary 
Center for Biological Investigation (Centro Multidisciplinar 
para Investigação Biológica–CEMIB) in the Division 
for the Study of Laboratory Animals at UNICAMP. 
The animals were maintained in collective cages (four 
animals per cage). The room temperature was maintained 
at 22°C ± 2°C in 12/12 h light–dark cycles with the light 
cycle starting at 6:30 am. We used 42, 12-week-old, 
male rats of the Wistar strain (Rattus norvegicus albinus, 
Rodentia, Mammalia), weighing 330 ± 2.45 g.
All normolipidemic animals were fed standard laboratory 
chow food (Nuvilab CR1; Nuvital Nutrients S.A., Brazil), and 
food and water were provided daily ad libitum.
Histological analysis
After the completion of the experiment, the aortic 
rings with endothelium (E+) and without endothelium (E–) 
were isolated and placed in formalin solution (200 mL of 
distilled water, 50 mL of 40% formaldehyde, and 250 mL 
of 0.2-M phosphate buffer (pH 7.4) for 24 h. Subsequently, 
the samples were washed with 70% ethanol and stored in 
formalin solution until paraffin embedding. For inclusion, 
dehydration was performed using an ascending series of 
ethyl alcohol solutions until the absolute concentration, 
clarification was performed in xylol (alcohol-xylol 1:1 and 
pure xylol), and inclusion was performed in xylol-paraffin 
(1:1). Inclusion and embedding were performed at 58°C in 
Paraplast Plus® (a mixture of paraffin, plastic polymers, and 
dimethylsulfoxide). The embedded aortic rings were glued 
on wooden blocks and cut into 2-mm-thick sections in a 
820 Spencer microtome (American Optical Corporation, 
USA). Approximately three sections were placed on each 
slide. After deparaffinization, the sections were stained with 
hematoxylin and eosin. The images were captured with a 
Nikon Eclipse 80i optical microscope coupled to a computer 
and video camera (Nikon Express Series, Shinagawa, Tokyo, 
Japan) and analyzed using NIS-Elements AR 3.0 software at 
a magnification of 40× and 100×14,15.
Measurement of blood pressure
To measure blood pressure, we used 10 rats randomly 
selected from the experimental groups. The catheterization 
procedure was performed, in which a cannula (PE 50) was 
inserted into the right carotid artery and connected to a strain 
gauge pressure transducer, which in turn was connected to an 
amplifier (MLS370/7 Blood Pressure Module; ADInstruments, 
Australia) and to a PowerLab 8/30 data acquisition system 
(ADInstruments, Australia). For data analysis, the LabChart Pro 
software (ADInstruments, Australia) was used14,15.
Analysis of Ru complexes
The complexes were characterized using elemental 
analysis, electronic spectroscopy in the infrared region, 
electron paramagnetic resonance (EPR), nuclear magnetic 
resonance (NMR), and electrochemical techniques (PPD, VC) 
by the research group of Dr. Elia Tfouni from the University 
of São Paulo (USP) in Ribeirão Preto.
Preparation of isolated aortic rings
The aortic rings were isolated and prepared according to 
the protocol established by Zanichelli et al16 The sample size 
was determined as described by Lenth17 using the Statistica 7.0 
software (StatSoft, Inc., USA), and the following parameters 
were used: minimum test power of 0.80 and alpha value 
prefixed at 0.05, and optimal number of experiments per 
experimental protocol equal to six. Based on these parameters, 
we used 14 experimental groups divided into aorta samples 
with endothelium (E+) and aorta samples without endothelium 
(E–), resulting in 28 experimental groups. 
The animals were sacrificed under deeper anesthesia. 
The chest was opened with a midline incision and the thoracic 
aorta portion was removed and divided into four rings, each 
with approximately 4 mm. 
The endothelium of two rings was removed mechanically 
from the inner surface of the aorta with the help of a cotton 
swab whereas the endothelial layer of the other two rings 
remained intact. Each ring was mounted on two L-shaped 
stainless steel hooks, and the smaller portion traversed the 
inside of the ring, after which these hooks were individually 
placed in a container containing 10 mL of Krebs–Hanseleit 
physiological solution (115.0 mM of NaCl, 4.6 mM of KCl, 
25.0 mM of NaHCO3, 2.5 mM of MgSO4.7H2O, 2.5 mM 
of CaCl2.2H2O, 1.2 mM of KH2PO4, 11.0 mM of glucose, 
and 0.11 mM of ascorbic acid) and coupled to an isometric 
voltage transducer16. The solution was maintained in a water 
bath at 37°C with the aid of an infusion pump and was 
constantly bubbled with 95% oxygen and 5% carbon dioxide 
for maintenance of pH. After placing the samples in the 
container, a voltage of 1.5 g was induced in the transducer 
and maintained throughout the experiment for both E+ 
and E− rings. For voltage recording, an isometric voltage 
transducer (BIOPAC System) containing a four-channel 
polygraph (MP-100, USA) was used. The rings were stabilized 
for 50 min and the Krebs–Hanseleit  solution was replaced 
every 20 min. 
After the stabilization period, the rings were precontracted 
with noradrenaline (NA, 10−6 M) dissolved in 2% ascorbic acid 
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and maintained in the bath throughout the assay. After voltage 
stabilization, a single concentration of the compound to be 
studied (10−6 M) was added to the bath and the recording was 
made without interruption for 120 min. Immediately after that, 
a single concentration of acetylcholine (ACh, 10−6 M) was added 
to the assay medium to confirm the presence or absence of 
endothelial cells and stabilize the response. In addition, sodium 
nitroprusside (SNP) at 10−6 M was added to verify the integrity 
of the vascular smooth muscle.
To complement the pharmacological investigation of the 
mechanism of action involved, i.e., after the first analysis of 
temporal concentration–effect curves, the involvement of the 
endogenous NO pathways, their mechanism of action via cyclic 
guanosine monophosphate (cGMP), and possible interference 
of endogenous eicosanoids were investigated. For this study, 
assays were conducted using the complexes cyclan NO 
(CyNO) and pyridine NO (PyNO) at 10−6 M using both E+ and 
E− rings, which were previously incubated with the following 
compounds: 10–30 mM of L-NAME hydrochloride (Enzo Life 
Sciences International, Inc. Plymouth Meeting, PA, USA)—a NO 
synthase inhibitor18,19, 5.6 µM of the cyclooxygenase inhibitor 
indomethacin (Enzo Life Sciences International, Inc. Plymouth 
Meeting, PA, USA)18, 3–10 µM of the soluble guanylate cyclase 
(GC) inhibitor ODQ (Enzo Life Sciences International, Inc. 
Plymouth Meeting, PA, USA)20, 10–300 µM of the NO sequester 
carboxy-PTIO (Enzo Life Sciences International (Plymouth 
Meeting, PA, USA).
To further evaluate the effect caused by these complexes, 
assays were performed using 10−6 M PyNO interacting 
with more than one enzyme inhibitor, e.g ., by the 
preincubation with L-NAME and indomethacin or with 
L-NAME, indomethacin, and ODQ, maintaining the specific 
concentration for each inhibitor.
All salts used for the preparation of the Krebs–Hanseleit 
solution were of American Chemical Society (ACS) standard. 
The NA stock solutions were prepared in 2% ascorbic acid and 
stored at −20°C for a maximum of 7 days. For the preparation 
of the indomethacin solution, a 5% sodium bicarbonate buffer 
was used. The dilutions were made in Krebs–Hanseleit buffer 
immediately before use and then discarded.
Statistical analysis
The results are presented as mean ± standard error of 
mean (SEM) of the percentage of response. Normality was 
confirmed using the Kolmogorov–Smirnov test. Student’s 
t test was used to compare the different experimental 
protocols for the following variables: response in the 
presence of vascular tone induced by NA, response before 
the addition of the compound, and response after different 
assay periods in the presence and absence of antagonists and 
enzyme inhibitors. Analysis of variance (ANOVA) followed 
by Dunnet test was performed to compare the areas under 
the curve. In all cases, p values of < 5% were accepted as 
indicating statistically significant differences. The curves 
were performed using GraphPad Prism software (GraphPad 
Software, San Diego, California, USA). 
Results
Blood pressure
The values of blood pressure of the study animals were 
similar to those previously reported for young adult rats with 
average weight and following anesthesia: systolic pressure of 
119.4 ± 3.862 mmHg, diastolic pressure of 92.75 ± 6.125 mmHg, 
and mean arterial pressure of 104.5 ± 4.29 mmHg, indicating that 
these animals were normotensive21-24.
Histological analysis
Histological analysis confirmed the experimental data, 
which indicated the presence or absence of endothelial 
cells (Figure 1).
Vascular reactivity
Corroborating histological data, the presence of endothelial 
cells was confirmed by the significant relaxation effect of ACh 
Figure 1 – Photomicrographs of (A) aortic rings with endothelium (E+) and (B) without endothelium (E−) isolated from normotensive rats (100×). The arrows indicate the 
presence of endothelial cells.
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on E+ aortic rings, and the integrity of the smooth muscle was 
confirmed by observing the relaxation in both E+ and E− aortic 
rings caused by sodium nitroprusside (SNP)18.
In contrast to the results of previous experiments 
demonstrating the induction of vascular tone only by NA, 
all tetraamines analyzed caused a significant decrease in the 
vascular tone (Figure 2).
After precontraction was performed with NA, the analyzed 
complexes caused increased vascular tone within 1 h after 
treatment, in both E+ and E− aortic rings, and decreased 
vascular tone 90 min after treatment (Figure 3).
In E− aortic rings, inhibition of GC significantly altered 
the contractile response induced by CyNO, causing vascular 
relaxation within 30 min. No significant responses were 
observed in E+ aortic rings (Figure 4). 
The contractile response induced by PyNO in E+ aortic 
rings significantly decreased after the inhibition of endothelial 
NO synthase (eNOS), cyclooxygenase, and GC. The inhibition 
of GC exerted a reducing effect within the first 60 min 
whereas the inhibition of eNOS and cyclooxygenase induced 
a contractile response after 120 min of incubation. In the 
absence of endothelial cells, only the inhibition of GC exerted 
a reducing effect (Figure 5).
With the aim to better understand the effect of such 
complexes, assays with the PyNO complex (10−6 M) were 
performed in the presence of more than one enzyme 
inhibitor, e.g., preincubation of aorta samples with L-NAME 
and indomethacin, with the aim to block the activity of 
endogenous NO and eicosanoids, such as prostacyclin (PGI2 
and TXA2). The simultaneous incubation of samples with 
L-NAME, indomethacin, and ODQ was also performed to 
eliminate the presence of other compounds in the same 
assay, including endogenous NO (synthesis and action) and 
endogenous eicosanoids (PGI2 and TXA2).
Therefore, when we blocked the endothelial function 
by inhibiting eNOS and cyclooxygenase, we observed 
a significant decrease in vascular tone in E+ aortic rings, 
confirming the direct action of the PyNO complex in smooth 
muscle. In contrast, no changes were observed in the vascular 
response using E− aortic rings.
When we blocked potential interferences in the activity 
of these complexes, i.e., preventing the synthesis of NO by 
blocking eNOS and preventing the action of eNOS by blocking 
GC as well as blocking potential interferences in the activity 
of PGI2 and TXA2 by blocking cyclooxygenases, we observed 
a decreased contractile response in both E+ and E− rings, 
corroborating the effect of PyNO directly on the smooth 
muscle (Figure 6).
The inhibiting effect of PyNO on the contractile function 
was not significantly different from that caused by the 
acetylation of 4-acPyNO in both E+ and E− aortic rings.
The results were also analyzed by calculating the areas 
under the curve (AUC). The response induced by PyNO, 
CyNO, and 4-acPyNO did not significantly differ for E+ and 
E− aortic rings (Table 1). On the other hand, the inhibition 
of eNOS by L-NAME caused a significant decrease in the 
response induced by PyNO and CyNO in E+ rings but not 
in E− rings. A similar effect was observed when we inhibited 
the cyclooxygenase pathway, resulting in a significant 
decrease in the response in E+ rings but not in E− rings. 
The GC inhibition by ODQ caused a significant decrease 
in the response induced by PyNO and CyNO in E− rings. 
Moreover, the sequestration of NO by C-PTIO did not affect 
the effect of the complexes evaluated.
Discussion 
The nitrosyl complexes of the class trans-[RuII(NH3)4(L)
(NO)]3+ are considered important molecules because of their 
low toxicity, good solubility in water, and ability to modulate 
the release of NO as a function of the trans effect played by 
the choice of ligand L, along with the fact that the reductive 
potential of NO+ is accessible to many reducing agents found 
in biological processes5,6. The nature of the ligand L is exactly 
what controls the strength of the Ru–NO bond so that the 
higher the binding property of the receptor, the weaker is 
the strength of the NO bond9. According to Tfouni et al4, 
the release or retention of NO is selective to the biological 
target, and a possible alternative would be the immobilization 
of complexes to silica, which could facilitate the action of 
reducing agents, possibly forming more stable compounds.
However, it was shown that the immobilization to silica 
does not modify compound reactivity, indicating that the 
properties of the Ru–NO bond may change depending on 
the nature of the ligand4.
A study conducted by Caramoni and Frenking26 
indicated that the use of tretraaza macrocyclic ligands, 
such as trans-[RuCl(NO)(Cyclan), as equatorial ligands 
promoted greater stability of the Ru–NO bond and thereby 
could be used as vasodilating agents9. However, studies in 
hypertensive rats using the complex trans-[RuII(NO+)(Cyclan)
Cl(PF6)2 indicated differences in the relaxation time when 
activated thermally (595 s) or by light irradiation (50 s)4.
Studies conducted in rat aortas demonstrated that the 
relaxation induced by the compound trans-[RuII(NO+)
(Cyclan)Cl(PF6)2 was inhibited under light irradiation and 
the amount of NO released was insufficient to affect the 
biological pathways4,27. Therefore, it is essential to evaluate the 
intensity and duration of relaxation, and for this reason, the 
measurement of KNO is important when assessing the duration 
of the vasorelaxant effect4.
Our results indicate that the vascular effect of the complexes 
tested involved decreased contractile tone followed by a 
relaxation effect after 90–120 min of incubation, suggesting 
that the assay time was not sufficient to effectively release NO. 
In addition, we can consider that the influence of the ligands 
pyridine and cyclan on the compounds helped to measure 
KNO, and consequently, the stabilization of the Ru–NO bond in 
order to release NO from the metallic complex more rapidly 
or more slowly.
The relaxation promoted by Ru II appears to be mediated 
by GC stimulation but has also been associated with the 
direct activation of K+ channels independently of cGMP, 
which indicates that Ru II is directly involved in the vascular 
relaxation promoted by NO. NO has a cGMP-dependent and 
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Figure 2 – Effect of tetraamines (A) CyNO−trans-[RuII(Cl)(NO)(Cyclan)](PF6)2, (B) PyNO−trans-[RuII(NH3)4(Py)(NO)]3+, and (C) 4-acPyNO−trans-[RuII(NH3)4(4-acPy)
(NO)]3+ 10−6 M in E+ aortic rings (■) and E− aortic rings (□) compared with control assays. *p value of < 0.05 using unpaired Student’s test for the values of vascular tone 
induced by NA (10−6 M). E+: PyNO, p = 0.0036; CyNO, p = 0.0008; 4-acPyNO, p = 0.0026; E–: PyNO, p = 0.0022; CyNO, p = 0.0022; 4-acPyNO, p = 0.0014.
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Figure 3 – Effect of tetraamines (A) CyNO−trans-[RuII(Cl)(NO)(Cyclan)](PF6)2, (B) PyNO−trans-[RuII(NH3)4(Py)(NO)]3+, and (C) 4-acPyNO−trans-[RuII(NH3)4(4-acPy)
(NO)]3+ 10−6 M after a single concentration of NA (10−6 M) in E+ aortic rings (■) and E− aortic rings (□). *p value of < 0.05 using unpaired Student’s t test for the values 
obtained immediately after administration of the compounds. E+: PyNO, p = 0.0195; CyNO, p = 00241; 4-acPyNO, p = 0.0116; E–: PyNO, p = 0.0216; CyNO, p = 0.0377; 
4-acPyNO, p = 0.0179.
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Figure 5 – Effect of PyNO−trans-[RuII(NH3)4(Py)(NO)]3+ on (A) E+ aortic rings and (B) E− aortic rings after treatment with enzyme inhibitors: L-NAME with E+ 
() and with E− (), indomethacin with E+ aorta () and with E− (), ODQ with E+ () and with E–(×), C-PTIO with E+ () and with E− (). *p value of 
< 0.05 using unpaired Student’s t test compared with the values  obtained in the absence of antagonists or enzyme inhibitors E+: PyNO vs. L-NAME,  
p = 0.0056; PyNO vs. indomethacin, p = 0.0459; PyNO vs. ODQ, p = 0.0043; E–: PyNO vs. ODQ, p = 0.0140.
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Figure 6 – Effect of PyNO–trans-[RuII(NH3)4(Py)(NO)]3+ 10−6 M on (A) E+ aortic rings and (B) E– aortic rings after incubating with the enzyme inhibitors L-NAME, 
indomethacin, and ODQ. *p value of < 0.05 using unpaired Student’s t test compared with the values obtained in the absence of antagonists or enzyme inhibitors. 
E+: PyNO vs. PyNO + L-NAME + indomethacin, p = 0.0056, and PyNO vs. PyNO + L-name + indomethacin + and ODQ, p = 0.0454.
Figure 4 – Effect of trans-[RuII(Cl)(NO)(Cyclan)](PF6)2−CyNO in (A) E+ aortic rings and (B) E− aortic rings after treatment with enzyme inhibitors L-NAME with E+ () 
and with E− (), indomethacin with E+ () and with E− (), ODQ with E+ () and with E–(×), C-PTIO with E+ () and with E– (). *p value of < 0.05 using unpaired 
Student’s t test compared with the values obtained in the absence of antagonists or enzyme inhibitors CyNO vs. ODQ with E–, p = 0.0152.
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Table 1 – Area under the curve of the Ru tetraamines trans-[RuII(Cl)(NO)(Cyclan)](PF6)2, trans-[RuII(NH3)4(Py)(NO)]3+, and trans-[RuII(NH3)4(4-acPy)(NO)]3+ 
in E+ aorta rings and E− aorta rings isolated from normotensive rats
trans- [RuII(Cl)(NO)(Cyclan)](PF6)2 trans-[Ru(NH3)4(Py)(NO)]3+ trans-[Ru(NH3)4(4-acPy)(NO)]3+
E+ E– E+ E– E+ E–
- 1.110,6 ± 225,6 1.068,7 ± 317,5 2.292,2 ± 520,6 1.069,4 ± 317,2 1.949,0 ± 542,4 1.292,9 ± 312,8
L-NAME (10-30 µM) 439,9 ± 75,0* 898,7 ± 250,6 852,4 ± 245,4* 898,6 ± 250,3 - -
Indomethacin  
(5,6 µM) 496,3 ± 92,4* 741,1 ± 161,9 796,07 ± 119,1* 740,7 ± 161,9 - -
ODQ (3-10 µM) 1.424,5 ± 453,1 646,3 ± 149,8 1.109,4 ± 388,4 646,7 ± 149,9 - -
C-PTIO (10-300 µM) 1.062,7 ± 159,9 646,3 ± 109,6 1.718,9 ± 276,8 1.223,7 ± 327,6 - -
L-NAME  
(10-30 µM), 
indomethacin 
(5,6µM) and ODQ 
(3-10µM)
- - 1.111,850 ± 350,891 1.329,567 ± 510,506 - -
The area under the curve of Ru tetraamines (AUC) trans-[RuII(Cl)(NO)(Cyclan)](PF6)2, trans-[RuII(NH3)4(Py)(NO)]3+, trans-[RuII(NH3)4(4-acPy)(NO)]3+, trans-[RuII(Cl)
(NO)(Cyclan)](PF6)2, and trans-[RuII(NH3)4(Py)(NO)]3+ are shown in the absence and presence of L-NAME, indomethacin, ODQ, and carboxy-PTIO in E+ aortic rings 
and E− aortic rings. 
*p value of < 0.05; Analysis of variance (ANOVA) followed by Dunnet and Student’s t test where appropriate. (−) Indicates the absence of assays with the enzyme 
inhibitors evaluated; AUC is shown as mean ± SEM as gF/min.
a cGMP-independent signaling pathway, which could directly 
activate the K+ channels28.
Another important factor involved in the onset of 
vasodilation in smooth muscle is the decreased concentration 
of cytosolic calcium through inhibition of calcium entry29. 
Previous studies have indicated that the NO/cGMP pathway 
can decrease the intracellular calcium concentration and 
thereby decrease the contractile sensitivity, resulting in smooth 
muscle relaxation4.
According to a study conducted by Lunardi et al30, confocal 
microscopy experiments indicated that trans-[RuII(NO+)([15]
aneN4)Cl]+, [RuII(NO+)(NH3NHQ)(terpy)]
3+ and cis-[RuII(NO+)
(bpy)2Cl](PF6)2 decreased calcium concentrations in 
the vasculature4.
Another study demonstrated that the relaxation induced 
by the complexes trans-[RuII(NO+)(cyclan)Cl]3+ and 
trans-[RuII(NO+)(NH3)4P(OEt)3]
3+ was completely blocked by 
the use of a NO sequester and GC inhibitors, suggesting that 
the mechanism of action is related to the NO/cGMP pathway4.
The present study corroborates the occurrence of changes 
associated with the NO/cGMP pathway, considering that GC 
inhibition promoted faster vascular relaxation in E− aortic rings 
by the CyNO complex, and this inhibition was also observed 
using the PyNO complex, suggesting a strong influence of 
the NO/cGMP pathway in the vascular effect induced by the 
compounds analyzed.
NO is the common mediator released from all vasodilator 
complexes, but its mechanism of action is distinguished by 
the specificity of activation of GC, which is different for each 
donor compound30. Considering that NO may also exist in 
a variety of forms, such as ion, and nitrosyl, and nitronium 
free radicals, NO released from Ru complexes may differ 
from NO produced by endothelial cells. This would explain 
the difference in potency and efficacy of NO donors in the 
induction of vascular relaxation30.
Conclusion
The results presented herein indicate that the vascular 
effect of the complexes evaluated involved decreased 
vascular tone induced by norepinephrine (10−6 M) at the 
end of the incubation period in rings with and without 
endothelium, indicating the slow release of NO from these 
complexes and suggesting that the ligands promoted chemical 
stability in the molecule. In addition, we demonstrated that 
the Ru–NO bond was more stable when pyridine and cyclan 
ligands were used in the formulation of the compound. 
Considering the protocol used, the effect induced by 
the compounds investigated on the vascular function of 
aortic rings with endothelium is partially dependent on the 
cyclooxygenase, guanylate cyclase, and eNOS pathways. 
On the other hand, only the guanylate cyclase pathway 
modulated the activity of these compounds on the aortic 
rings without endothelium.
To date, several Ru complexes have been synthesized and 
tested for their potential therapeutic use and their effects and 
mechanisms of action are being intensely studied by different 
research groups. However, many details remain unknown and 
will be elucidated using multidisciplinary studies. 
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